Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.
Quote | Alk-Abello A/S (OTCMKTS:AKBLF)
Last: | $21.68 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $21.68 |
High: | $0 |
Low: | $0 |
Volume: | 2,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Alk-Abello A/S (OTCMKTS:AKBLF)
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
2024-05-05 04:03:38 ET ALK-Abelló A/S (AKBLF) Q1 2024 Results Conference Call May 03, 2024 06:30 AM ET Company Participants Per Plotnikof - Head of Investor Relations Peter Halling - Chief Executive Officer Claus Steensen Solje - Chief Financial Officer ...
Message Board Posts | Alk-Abello A/S (OTCMKTS:AKBLF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...